Alys Puts Skin In The Dermatology Game With $100m Launch
Having adopted a similar model to set up Centessa, investment firm Medicxi is merging six of its portfolio companies to create an ambitious immuno-dermatology group.
You may also be interested in...
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
The Belgian drugmaker’s faith in the psoriasis drug is looking to be well placed and with other indications coming aboard, sales forecasts of around €5bn-6bn for the pipeline-in-a-product seem very achievable.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.